ARDP0006

CAS No. 81-55-0

ARDP0006( —— )

Catalog No. M22403 CAS No. 81-55-0

ARDP0006 is an inhibitor of NS2B-NS3 protease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG 47 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ARDP0006
  • Note
    Research use only, not for human use.
  • Brief Description
    ARDP0006 is an inhibitor of NS2B-NS3 protease.
  • Description
    ARDP0006 is an inhibitor of NS2B-NS3 protease.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    NS2B-NS3
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    81-55-0
  • Formula Weight
    330.2
  • Molecular Formula
    C14H6N2O8
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 41.67 mg/mL (126.19 mM)
  • SMILES
    Oc1ccc(c2C(=O)c3c(ccc(O)c3C(=O)c12)[N+]([O-])=O)[N+]([O-])=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Justin Jang Hann Chu, Regina Ching Hua Lee, Melgious Jin Yan Ang,et al.Antiviral activities of 15 dengue NS2B-NS3 protease inhibitors using a human cell-based viral quantification assay.Antiviral Res. 2015 Jun;118:68-74. doi: 10.1016/j.antiviral.2015.03.010. Epub 2015 Mar 27.
molnova catalog
related products
  • Chiirirhamnin

    Chiirirhamnin is a natural product from Aconitum chiisanense.

  • Trimethoxystilbene

    3, 5, 4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast Y cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.

  • PF-00835231

    PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.